The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.
Lead Sponsor: HaEmek Medical Center, Israel
|Source||HaEmek Medical Center, Israel|
The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy.
In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.
The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.
Clinical and laboratory characteristics related to the spleen in SCA patients will be studied.
Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.
In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.
|Start Date||February 2009|
|Completion Date||August 2010|
|Primary Completion Date||August 2010|
Sampling Method: Probability Sample
Inclusion Criteria: - All the patients followed up at the Pediatric Hematology Unit Exclusion Criteria: - Patients lost from follow up of with insufficient data
- All the patients followed up at the Pediatric Hematology Unit
- Patients lost from follow up of with insufficient data
Minimum Age: 1 Year
Maximum Age: 35 Years
Healthy Volunteers: No
Type: Principal Investigator
Investigator Affiliation: HaEmek Medical Center, Israel
Investigator Full Name: Dr Koren Ariel
Investigator Title: Head of Pediatric Hematology Unit and Pediatric Dpt B
|Has Expanded Access||No|
Label: Sickle Cell Patients
Description: Patients with homozygous Sickle Cell Anemia
Label: Sickle Cell Thalassemia
Description: Patients with Sickle Cell Thalassemia
|Study Design Info||
Observational Model: Cohort
Time Perspective: Retrospective